Get Sample Report @ https://www.wiseguyreports.com/sample-request/740557-gliosarcoma-pipeline-review-h2-2016
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 12, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Gliosarcoma.
Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Gliosarcoma Overview 8
Therapeutics Development 9
Pipeline Products for Gliosarcoma - Overview 9
Pipeline Products for Gliosarcoma - Comparative Analysis 10
Gliosarcoma - Therapeutics under Development by Companies 11
Gliosarcoma - Therapeutics under Investigation by Universities/Institutes 13
Gliosarcoma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Gliosarcoma - Products under Development by Companies 16
Gliosarcoma - Products under Investigation by Universities/Institutes 17
Gliosarcoma - Companies Involved in Therapeutics Development 18
Amgen Inc. 18
Axelar AB 19
Bristol-Myers Squibb Company 20
Burzynski Research Institute, Inc. 21
Celgene Corporation 22
Cortice Biosciences, Inc. 23
ERC Belgium SA 24
Merck & Co., Inc. 25
Millennium Pharmaceuticals Inc 26
NewLink Genetics Corporation 27
Novartis AG 28
Nuo Therapeutics, Inc. 29
Progenics Pharmaceuticals, Inc. 30
Triphase Accelerator Corporation 31
Gliosarcoma - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 37
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
ALD-451 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
alisertib - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Antineoplaston Therapy - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Access Report @ https://www.wiseguyreports.com/reports/740557-gliosarcoma-pipeline-review-h2-2016
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349
Website: http://www.wiseguyreports.com
Release ID: 146579